Form 4: CYTK Director Boosts Stake via Equity Program

Cytokinetics Director Nancy Wysenski acquired 99 shares of common stock at $62.80 per share as part of an equity in lieu of cash retainer program, increasing her total beneficial ownership to 30,873 shares.

Summary

• Nancy Wysenski, a Director at Cytokinetics Inc. (CYTK), acquired 99 shares of the company's common stock.
• The transaction took place on October 15, 2025, with shares priced at $62.80 each.
• This acquisition was executed under the company's director equity in lieu of cash retainer program.
• Following this transaction, Ms. Wysenski's direct beneficial ownership in Cytokinetics Inc. stands at 30,873 shares of common stock.

Sentiment

Score: 6

Explanation: The acquisition of shares by a director, even as part of an equity compensation program, generally indicates alignment of interests and a degree of confidence in the company's future, contributing to a slightly positive sentiment.

Positives

• A Director increased their direct ownership in the company, which can signal confidence in the company's future prospects.
• The acquisition was part of a director equity program, aligning the director's financial interests more closely with those of shareholders.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The acquisition of 99 shares of common stock by Director Nancy Wysenski as part of the director equity in lieu of cash retainer program constitutes a related party transaction between the company and its director.

Stakeholder Impact

• Shareholders: The transaction increases the alignment of Director Nancy Wysenski's financial interests with those of the shareholders due to her increased equity ownership.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this routine insider transaction report.

Key Dates

Keywords

CYTOKINETICS, CYTK, Form 4, Insider Transaction, Director, Common Stock, Share Acquisition, Equity Compensation